26 October 20214 minute read

DLA Piper advises Agena Biosciences in its sale to Mesa Labs

DLA Piper represented Agena Biosciences, Inc. in its sale to Mesa Labs (NASDAQ:MLAB), a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare and medical device industries.

Headquartered in San Diego, Agena is a leading clinical genomics tools company that develops, manufactures and supplies highly sensitive, low-cost, high-throughput genetic analysis solutions to clinical labs and development partners globally.

“It was a pleasure to advise Agena and its board since its inception and on its sale to Mesa Labs, which will allow Agena to help deliver innovative new technologies for clinical genomics,” said Michael Brown, the DLA Piper partner who represented Agena since its inception. “We brought together our exceptional transactional experience and our deep understanding of the life sciences and healthcare fields to facilitate this deal for Agena, and we look forward to their continued success,” said David Clark, the DLA Piper partner who led the deal team along with Brown.

“Mike, David and the rest of the DLA Piper team have provided exceptional guidance and support to Agena from the launch of the company all the way to its acquisition, and we are grateful for their hard work, consistent responsiveness and high level of legal skill throughout our working relationship,” said Pete Dansky, CEO of Agena.

In addition to Clark and Brown (both of San Diego), the DLA Piper team representing Agena in its sale included Sam Esan, Kathryn Fortin, Neil Balmert, Michelle Lara (all of San Diego), Paolo Morante (New York), Nick Gerlach (Silicon Valley), Sarah Thompson Schick (Austin) and Sarah Tauman (San Francisco).

With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex cross-border transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 11 consecutive years, according to Mergermarket.

DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients. Recognizing that clients’ needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company.